Compare Tesla, Inc. (TSLA) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tesla, Inc. vs GeneDx Holdings Corp — how do they compare? Tesla, Inc. trades at $366.62 (market cap $1.45T), while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: Tesla, Inc. is far larger — about 566.4× GeneDx Holdings Corp's market cap. Which is the better fit depends on your goals.
| TSLA | WGS | |
|---|---|---|
Market Cap | $1.45T | $2.56B |
Sector | Consumer Cyclical | Technology |
52-Week High | $489.88 | $167.51 |
52-Week Low | $298.16 | $34.51 |
Enterprise Value | $1.43T | $2.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tesla (TSLA) trades at $368.16, up 3.98% today, amid a bullish technical signal and recent earnings beats despite a Q2 2026 miss. The stock shows elevated valuation multiples with a P/E of 340.89 and P/S of 12.57, while profitability metrics like a 3.67% net income margin reflect competitive pressures. Positive developments include regulatory approval for driver-assistance software in Europe and a potential cheaper EV launch, though cash flow trends indicate heavy investment spending.
The outlook balances innovation potential in autonomy and energy against valuation concerns and execution risks. Near-term catalysts include Q3 2026 earnings, with the consensus price target of $398.38 suggesting modest upside. Key risks are slowing auto demand, high capex, and reliance on future technology adoption to justify current premiums.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
